Class IITerminatedD-0875-2022
Drug recall · May 25, 2022
GaviLyte -C recall
Why: Failed Stability Specification
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19
- Lots / codes
Lot # S001132, exp. date July 2022 NDC # 43386-060-19
- Quantity
- 26,910 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed nationwide, including Puerto Rico.
- Initiated
- April 27, 2022 · Voluntary: Firm initiated
- Classified
- May 16, 2022
- Reported
- May 25, 2022
- Ended
- April 13, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch GaviLyte-C
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.